Commentary: British biotech industry lagging

09/14/2004 | Guardian (London), The

Heather Tomlinson of The Guardian writes that her country's slow growth in the biotechnology sector is partly the result of U.S. firms reaping most of the financial gains from highly effective drugs for rheumatoid arthritis, such as Remicade, Enbrel and Humira, all developed by British scientists. She says the U.K. biotechnology industry lags behind because, unlike its American counterparts, it fails to make its research findings commercially viable, and many companies are unwilling to take the financial risk necessary to bring new therapies to the market.

View Full Article in:

Guardian (London), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY